90 related articles for article (PubMed ID: 1987306)
21. Mineral metabolism and calcitriol therapy in idiopathic juvenile osteoporosis.
Saggese G; Bertelloni S; Baroncelli GI; Perri G; Calderazzi A
Am J Dis Child; 1991 Apr; 145(4):457-62. PubMed ID: 2012031
[TBL] [Abstract][Full Text] [Related]
22. Hypomagnesemia and the parathyroid hormone-vitamin D endocrine system in children with insulin-dependent diabetes mellitus: effects of magnesium administration.
Saggese G; Federico G; Bertelloni S; Baroncelli GI; Calisti L
J Pediatr; 1991 Feb; 118(2):220-5. PubMed ID: 1993948
[TBL] [Abstract][Full Text] [Related]
23. Parathyroid hormone responsiveness in hypoparathyroidism with hypomagnesemia.
Michelis MF; Bragdon RW; Fusco RD; Eichenholz A; Davis BB
Am J Med Sci; 1975; 270(3):412-8. PubMed ID: 1211404
[TBL] [Abstract][Full Text] [Related]
24. Magnesium Modifies the Impact of Calcitriol Treatment on Vascular Calcification in Experimental Chronic Kidney Disease.
Zelt JG; McCabe KM; Svajger B; Barron H; Laverty K; Holden RM; Adams MA
J Pharmacol Exp Ther; 2015 Dec; 355(3):451-62. PubMed ID: 26487689
[TBL] [Abstract][Full Text] [Related]
25. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man.
Mavichak V; Coppin CM; Wong NL; Dirks JH; Walker V; Sutton RA
Clin Sci (Lond); 1988 Aug; 75(2):203-7. PubMed ID: 3409636
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and biologic effects of calcitriol in normal humans.
Levine BS; Singer FR; Bryce GF; Mallon JP; Miller ON; Coburn JW
J Lab Clin Med; 1985 Feb; 105(2):239-46. PubMed ID: 3838330
[TBL] [Abstract][Full Text] [Related]
27. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin.
Lam M; Adelstein DJ
Am J Kidney Dis; 1986 Sep; 8(3):164-9. PubMed ID: 3752072
[TBL] [Abstract][Full Text] [Related]
28. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group.
Wadler S; Haynes H; Beitler JJ; Goldberg G; Holland JF; Hochster H; Bruckner H; Mandeli J; Smith H; Runowicz C
J Clin Oncol; 1993 Aug; 11(8):1517-22. PubMed ID: 8393097
[TBL] [Abstract][Full Text] [Related]
29. cis-Diamminedichloroplatinum-induced hypomagnesemia and renal magnesium wasting.
Bell DR; Woods RL; Levi JA
Eur J Cancer Clin Oncol; 1985 Mar; 21(3):287-90. PubMed ID: 4040020
[TBL] [Abstract][Full Text] [Related]
30. Effect of serum magnesium concentration on renal handling of phosphate in a patient with primary hypomagnesemia.
Nishiyama S; Mitsubuchi H; Ikuta M; Ohta T; Matsuda I
Endocrinol Jpn; 1988 Feb; 35(1):159-64. PubMed ID: 3396512
[TBL] [Abstract][Full Text] [Related]
31. Magnesium homeostasis following chemotherapy with cisplatin: a prospective study.
Stewart AF; Keating T; Schwartz PE
Am J Obstet Gynecol; 1985 Nov; 153(6):660-5. PubMed ID: 4061536
[TBL] [Abstract][Full Text] [Related]
32. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats.
Mavichak V; Wong NL; Quamme GA; Magil AB; Sutton RA; Dirks JH
Kidney Int; 1985 Dec; 28(6):914-21. PubMed ID: 4087697
[TBL] [Abstract][Full Text] [Related]
33. Hypermagnesemia, serum calcium, and parathyroid hormone levels.
Wilson TA; Gopalakrishnan L; Trager G; Kapoor A
N Engl J Med; 1984 Aug; 311(9):601. PubMed ID: 6749235
[No Abstract] [Full Text] [Related]
34. Primary familial hypomagnesemia syndrome: a new approach in treatment.
Nesibe A; Sinasi O
J Pediatr Endocrinol Metab; 2012; 25(5-6):599-602. PubMed ID: 22876566
[TBL] [Abstract][Full Text] [Related]
35. Primary idiopathic hypomagnesemia in two female siblings.
Challa A; Papaefstathiou I; Lapatsanis D; Tsolas O
Acta Paediatr; 1995 Sep; 84(9):1075-8. PubMed ID: 8652964
[TBL] [Abstract][Full Text] [Related]
36. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer.
Markmann M; Rothman R; Reichman B; Hakes T; Lewis JL; Rubin S; Jones W; Almadrones L; Hoskins W
J Cancer Res Clin Oncol; 1991; 117(2):89-90. PubMed ID: 2007614
[TBL] [Abstract][Full Text] [Related]
37. Renal function, serum calcium and magnesium during treatment of advanced bladder carcinoma with cis-dichlorodiamineplatinum: impact of tumour site, patient age and magnesium suppletion.
Blom JH; Kurth KH; Splinter TA
Int Urol Nephrol; 1985; 17(4):331-9. PubMed ID: 3835175
[TBL] [Abstract][Full Text] [Related]
38. Hypomagnesemia following high-dose intracavitary cisplatin with systemically administered sodium thiosulfate.
Markman M; Cleary S; Howell SB
Am J Clin Oncol; 1986 Oct; 9(5):440-3. PubMed ID: 3776908
[TBL] [Abstract][Full Text] [Related]
39. Cis-platinum-induced renal sodium wasting.
Lammers PJ; White L; Ettinger LJ
Med Pediatr Oncol; 1984; 12(5):343-6. PubMed ID: 6541750
[TBL] [Abstract][Full Text] [Related]
40. [Hypocalcemia induced by cisplatin. Inappropriate parathyroid response due to hypomagnesemia].
Chauffert B; Chevet D; Chantereau MJ; Tanter Y; Charffedine K; Lorcerie B
Presse Med; 1991 Aug 31-Sep 7; 20(27):1288-9. PubMed ID: 1832768
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
